EPGL!The hottest penny on the market!! current share

New Post Public Reply Private Reply Replies (0) Message Board
steelerfan7

EPGL!The hottest penny on the market!!

current share structure 5 billion authorized, 499 million outstanding in float. 4.5 billion restricted.

EP Global Communications, Inc. is a new medical device company, publicly trading as ticker symbol EPGL. We look forward to updating shareholders often.

Irvine, CA · http://www.epglmed.com

EPGL Med team now establishing distribution channels in US, Asia and Europe for MPDD rollout 2013.


EPGL Team sets goal of selling 10,000 MPDD units 2013. 600,000 Physicians in US and 15 million physicians worldwide.


EPGL has declined a $6mm offer by an Investment Banker to purchase 1/3 of Company's authorized shares.


We will be marketing to doctors through many channels, including HMO relationships, US Military relationships, Conferences and Media.


We have had doctors actually contacting us about the MPDD and when it will be available.


We chose EPGL because it was a manageable restructuring opportunity whereby we could create a win, win, win outcome.


we chose EPGL because of the unique circumstances and the opportunity it represented with debt conversion to equity.


No, there will be no more reverse splits. As we have stated, we will not entertain past methods. There are better ways to grow a company.


we can only say the stock will get more awareness. We are going to increase IR/PR awareness, through reputable avenues only.


We plan to be at a market capitalization commensurate with other like medical device companies.


we believe we can achieve the necessary requirements for OTCQX.


First priority is to move EPGL to Current Information on Pinksheets and execute from there on requisite reporting for OTCQX.


We anticipate OTCQX will happen mid 2013. This is our plan.


cannot go into detail on stock awareness other than upcoming news and events will undoubtedly make more investors aware of EPGL.


"Proper diagnosis is 90% of the challenge when dealing with an extremely difficult patient (chronic pain)." Physical Therapist, GA


"I can only imagine the number of interventional procedures and even surgery that are performed needlessly... " Primary Physician, CA


"I see multiple patients day in and day out that would benefit from using this device." Pain Physician, FL


EPGL now in discussions with major HMO's to provide physicians with group pricing benefits on our products.


Primary care physicians, pain physicians, and physical therapists are just a few examples of the professionals who need the MPDD.


Millions of patients are on narcotics unnecessarily because of misdiagnosis of pain. MPDD will help physicians alleviate this problem.


Physicians worldwide need the MPDD. Currently physicians have no accurate way to determine origination of muscle related pain.


Lonnie, yes, we plan to become fully reporting by year end with OTC and SEC. Doing housekeeping to that end right now.


Viking, we plan to market US only first half 2013, then open Europe and Asia distribution second half 2013


we are making moves to make EPGL trade as easy as possible with all brokers. There has been a lot of housekeeping to do.






Scroll down for more posts ▼

Top 10 Most Recent News Articles

Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 6

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 2

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 2

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 3

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 4

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 2

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading

Top 5 Most Recently Viewed Articles

Halozyme's Upcoming Investment Presentation at Healthcare Conference

Updated Category News Views 277

Halozyme's Participation in Major Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) is set to showcase its advancements at an important healthcare conference. Dr. Helen Torley, the president and CEO, will present and engage in investor meetings, highlighting the company's innovative approaches in the biopharmaceutical sector. Details of the Presentation The...

Continue Reading
Revitalizing Everyday Sound: viaim's Collaboration with Orchestra

Updated Category News Views 181

Transforming Everyday Listening through Technology In an exciting development for audio enthusiasts, viaim, an innovative AI audio brand, has joined forces with the prestigious China Philharmonic Orchestra. This dynamic collaboration has given birth to the "Philharmonic Signature Sound," an advanced acoustic system meticulously designed to replicate the immersive...

Continue Reading
Unlocking the Future of Payments: Early Access for Wirex Pay Users

Updated Category News Views 103

Wirex Pay Revolutionizes Crypto Payments with Early Access Wirex Pay, a groundbreaking decentralized payment network, is thrilled to announce its innovative crypto payment application is now available for early access to select users. This opportunity marks a significant step towards the next wave of digital transactions, integrating cryptocurrencies into everyday...

Continue Reading
Inspire Investing Introduces New Fund Names for Better Clarity

Updated Category News Views 172

Inspire Investing Reveals Name Changes for ETFs Inspire Investing, renowned as the largest provider of faith-based ETFs, has announced significant updates to the names of two of its exchange-traded funds. These changes, aimed at increasing clarity regarding the funds' investment strategies, reflect Inspire's commitment to aligning their product offerings with investor...

Continue Reading
BASF's Recent Challenges Impact Earnings and Cash Flow Performance

Updated Category News Views 105

BASF Faces Headwinds in Latest Earnings Report Shares of BASF SE (OTC: BASFY) decreased by 2% following the publication of its third-quarter results. The company struggled to meet expectations across various divisions despite evidence of resilience in specific areas. Financial Performance Analysis BASF reported an adjusted EBITDA of €1,622 million, which is a notable 3%...

Continue Reading